Lauren Riker Sells $143,702 in PCRX Shares

Senior VP Lauren Riker sold 6,115 shares of PCRX on June 11, 2026.

Written by Opentrades · Published Jun 12, 2026, 10:01 PM EDT · Updated Jun 13, 2026, 1:00 AM EDT

Key Points

Lauren Riker, Senior Vice President of Finance at PCRX, sold 6,115 shares on June 11, 2026, for a total of $143,702.50.
PCRX shares recently traded at $22.99, with analysts maintaining varied ratings and price targets ranging from $24 to $38.
Other funds like BlackRock and Vanguard have adjusted their positions in PCRX, with BlackRock reducing and Vanguard increasing their holdings.

Lauren Riker, who serves as the Senior Vice President of Finance at PCRX, recently sold 6,115 shares of the company. The transaction took place on June 11, 2026, at an average price of $23.50 per share, amounting to a total value of $143,702.50. This planned sale was executed under a pre-arranged trading plan.

Other Institutional Activity in PCRX

Several institutional investors have also adjusted their holdings in PCRX. BlackRock, Inc. reduced its position by 328,937 shares, ending with 6,735,343 shares valued at approximately $152.2 million. Vanguard Portfolio Management LLC increased its stake significantly by adding 2,501,286 shares, bringing its total to 2,501,286 shares worth about $56.5 million. Meanwhile, Dimensional Fund Advisors LP boosted its holdings by 110,584 shares, resulting in a total of 2,060,597 shares valued at roughly $46.6 million.

PCRX Stock Snapshot

Shares of PCRX recently traded at $22.99. The company has seen some movement in its stock, with analysts maintaining various ratings. The stock has been the subject of recent analyst reports, with price targets ranging from $24 to $38.

Insider Buying and Selling at Pacira BioSciences, Inc.

In addition to Lauren Riker's sale, other insiders have been active in PCRX. On June 10, 2026, Michael Yang acquired 6,405 shares, and Christopher Christie also bought 6,405 shares. Laura Brege purchased 10,891 shares and an additional 6,405 shares on the same day. These transactions were not part of a pre-planned trading strategy.

Analysts Set New Price Targets

On May 1, 2026, RBC Capital maintained a 'hold' rating on PCRX with a $24 target. Needham also maintained its 'buy' rating with a $32 target. Barclays, on March 26, 2026, reiterated a 'hold' rating with a price target of $25. Analysts have a consensus recommendation of 'buy', with an average target price indicating potential upside.

Bottom Line

Lauren Riker's planned sale of PCRX shares highlights ongoing insider activity at the company. Investors often track such transactions for potential insights into company prospects. It's important to remember that these trades are disclosed after they occur and may not reflect current insider sentiment. As always, these filings are historical and provide a snapshot of past activity.